Intramyocardial, Autologous CD34+Cell Therapy for Refractory Angina

被引:376
|
作者
Losordo, Douglas W. [1 ]
Henry, Timothy D. [2 ]
Davidson, Charles
Lee, Joon Sup [3 ]
Costa, Marco A. [4 ]
Bass, Theodore [5 ]
Mendelsohn, Farrell [6 ]
Fortuin, F. David [7 ]
Pepine, Carl J. [8 ]
Traverse, Jay H. [2 ]
Amrani, David [9 ]
Ewenstein, Bruce M. [9 ]
Riedel, Norbert [9 ]
Story, Kenneth [9 ]
Barker, Kerry [9 ]
Povsic, Thomas J. [10 ]
Harrington, Robert A. [10 ]
Schatz, Richard A. [11 ]
机构
[1] Northwestern Univ, NW Mem Hosp, Program Cardiovasc Regenerat Med, Div Cardiol, Chicago, IL 60611 USA
[2] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[5] Shands Jacksonville Med Ctr, Jacksonville, FL USA
[6] Ctr Therapeut Angiogenesis, Birmingham, AL USA
[7] Mayo Clin, Scottsdale, AZ USA
[8] Univ Florida, Gainesville, FL USA
[9] Baxter Healthcare Corp, Deerfield, IL 60015 USA
[10] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[11] Scripps Green Hosp, La Jolla, CA USA
关键词
angiogenesis; endothelial progenitor cells (EPC) myocardial ischemia; myocardial regeneration; stem cells; PERCUTANEOUS CORONARY INTERVENTION; MYOCARDIAL-INFARCTION; UNIVERSAL DEFINITION; CELL TRANSPLANTATION; RANDOMIZED-TRIAL; RESEARCH ISSUES; ARTERY-DISEASE; HEART-DISEASE; DOUBLE-BLIND; ANGIOGENESIS;
D O I
10.1161/CIRCRESAHA.111.245993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function. Objective: Evaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options. Methods and Results: In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1X10(5) or 5X10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8 +/- 1.1 versus 10.9 +/- 1.2, P=0.020) and 12 months (6.3 +/- 1.2 versus 11.0 +/- 1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139 +/- 151 versus 69 +/- 122 seconds, P=0.014; 12 months: 140 +/- 171 versus 58 +/- 146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients. Conclusions: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies. (Circ Res. 2011;109:428-436.)
引用
收藏
页码:428 / 436
页数:9
相关论文
共 50 条
  • [41] Ideal or actual body weight to calculate CD34+cell doses for autologous hematopoietic stem cell transplantation?
    Ali, MY
    Oyama, Y
    Monreal, J
    Winter, JN
    Tallman, MS
    Williams, SF
    Singhal, S
    Gordon, LI
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2003, 31 (10) : 861 - 864
  • [42] Ideal or actual body weight to calculate CD34+cell doses for autologous hematopoietic stem cell transplantation?
    Ali, Y
    Oyama, Y
    Monreal, J
    Winter, J
    Tallman, M
    Williams, S
    Singhal, S
    Gordon, L
    Mehta, J
    BLOOD, 2001, 98 (11) : 201A - 202A
  • [43] Monitoring of peripheral blood CD34+cell counts on the first day of apheresis is highly predictive for efficient CD34+cell yield
    Demirer, T
    Ilhan, O
    Ayli, M
    Arat, M
    Dagli, M
    Ozcan, M
    Haznedar, R
    Genc, Y
    Fen, T
    Ayyildiz, E
    Dincer, S
    Arslan, O
    Gurman, G
    Konuk, N
    Dalva, K
    Uysal, A
    Koc, H
    Ozet, G
    Akan, H
    THERAPEUTIC APHERESIS, 2002, 6 (05): : 384 - 389
  • [44] Reliable Correlation of CD34+Cell Count by Two Different Methods Enables CD34+Cell Count-guided Leukaphaeresis
    Sorigue, M.
    Alonso Nogues, E.
    Vergara, S.
    Linio, R.
    Azqueta, C.
    Querol, S.
    Junca, J.
    Grifols, J.
    TRANSFUSION, 2015, 55 : 99A - 99A
  • [45] Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina
    Briguori, C
    Reimers, B
    Sarais, C
    Napodano, M
    Pascotto, P
    Azzarello, G
    Bregni, M
    Porcellini, A
    Vinante, O
    Zanco, P
    Peschle, C
    Condorelli, G
    Colombo, A
    AMERICAN HEART JOURNAL, 2006, 151 (03) : 674 - 680
  • [46] CD34+cell analysis: Multicenter cooperative trials
    Dzik, S
    MOLECULAR BIOLOGY IN BLOOD TRANSFUSION, 2000, 35 : 147 - 158
  • [47] Ex vivo expanded CD34+cell therapy for chronically injured liver in rats
    Nakamura, Toru
    Torimura, Takuji
    Masuda, Hiroshi
    Iwamoto, Hideki
    Hashimoto, Osamu
    Koga, Hironori
    Abe, Mitsuhiko
    Ueno, Takato
    Sato, Michio
    HEPATOLOGY, 2012, 56 : 331A - 331A
  • [48] Phase III clinical trial of autologous CD34+cell transplantation to accelerate fracture nonunion repair
    Kuroda, Ryosuke
    Niikura, Takahiro
    Matsumoto, Tomoyuki
    Fukui, Tomoaki
    Oe, Keisuke
    Mifune, Yutaka
    Minami, Hironobu
    Matsuoka, Hiroshi
    Yakushijin, Kimikazu
    Miyata, Yoshiharu
    Kawamoto, Shinichiro
    Kagimura, Tatsuo
    Fujita, Yasuyuki
    Kawamoto, Atsuhiko
    BMC MEDICINE, 2023, 21 (01)
  • [49] A Proof-of-Concept Study of CD34+Cell Therapy for Diabetic Kidney Disease
    Pergola, Pablo E.
    Mandava, Swetha
    Sietsema, William K.
    Bartel, Ronnda L.
    Schumacher, Ann M.
    Sharma, Surabhi
    Ghuman, Sapna K.
    Buck, Kristen K.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 914 - 914
  • [50] Comparing the Effects of MSCs and CD34+Cell Therapy in a Rat Model of Myocardial Infarction
    Shalaby, Sally M.
    El-Shal, Amal S.
    Zidan, Haidy E.
    Mazen, Nehad F.
    Abd El-Haleem, Manal R.
    Abd El Motteleb, Dalia M.
    IUBMB LIFE, 2016, 68 (05) : 343 - 354